VIA
MAZE

Virtus Investment Advisers’s Maze Therapeutics MAZE Stock Holding History

Virtus Investment Advisers’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Buy
7,016
+170
+2% +$7.5K 0.06% 337
2025
Q4 		$284K Sell
6,846
-1,551
-18% -$53.3K 0.08% 266
2025
Q3 		$218K Buy
8,397
+1,457
+21% +$24.6K 0.06% 253
2025
Q2 		$85.2K Buy
+6,940
New +$72.2K 0.03% 401

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtus Investment Advisers's MAZE Position: Q1 2026 in Review

Virtus Investment Advisers increased its Maze Therapeutics (MAZE) stake by 2.5% in Q1 2026, buying an estimated $7.5K and bringing the position to 7,016 shares worth $209K. The position accounts for 0.06% of the portfolio, ranked #337.

Virtus Investment Advisers first reported a position in MAZE in Q2 2025 and has held it in 4 quarters since. The position peaked at $284K in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Virtus Investment Advisers held 7,016 shares of Maze Therapeutics worth $209K as of Q1 2026.
  • Virtus Investment Advisers bought 170 Maze Therapeutics shares in Q1 2026, an estimated $7.5K.
  • Maze Therapeutics made up 0.06% of Virtus Investment Advisers's portfolio in Q1 2026, its #337 holding.
  • Virtus Investment Advisers first reported a position in Maze Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Virtus Investment Advisers's Maze Therapeutics position peaked at $284K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.